Biliary Atresia Clinical Trial
Official title:
Biliary Atresia Study in Infants and Children (BASIC)
Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To identify polymorphisms that may be important in disease progression such as HLA polymorphisms; To characterize the natural history of the older, non-transplanted child with BA.
Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. A variety of genetic, autoimmune and environmental influences have been hypothesized to be important. Most studies to date have focused on the neonate and young child with BA, yet the older surviving child with BA can provide important information about genetics, as well as, natural history. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following hypotheses: Hypothesis 1: A genetic defect is a likely causative factor for BA among children with BA and multiple congenital anomalies. Hypothesis 2: Autoimmune factors are likely to contribute to disease progression or acquisition and can be identified by correlating HLA among children with BA to healthy controls and by comparison of those who develop early complications including, variceal bleed, ascites, and growth failure compared to those who do not. Hypothesis 3a: Sentinel events such as variceal bleeding, ascites and growth failure are earlier predictors of death or need for liver transplantation than the pediatric end-stage liver disease score (PELD). Hypothesis 3b: Health related quality of life will be impaired compared to healthy age matched children and relate to severity of illness. Hypothesis 3c: Growth failure as measured by anthropometrics and nutritional supplementation will be predictive of onset of sentinel events (ascites, variceal bleed, death, and transplant) in the following 24 months. This study will be performed by the Childhood Liver Disease Research Network (ChiLDReN), a National Institute of Diabetes & Digestive and Kidney Diseases (NIDDK) funded network. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03667534 -
Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
|
||
Completed |
NCT02652533 -
Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia
|
||
Completed |
NCT01443572 -
The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation
|
N/A | |
Recruiting |
NCT04373941 -
Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia
|
Phase 2 | |
Completed |
NCT01854827 -
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
|
Phase 1/Phase 2 | |
Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
Recruiting |
NCT05848310 -
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
|
||
Recruiting |
NCT05072626 -
High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
|
||
Completed |
NCT02292862 -
Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation
|
N/A | |
Completed |
NCT00294684 -
A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy
|
N/A | |
Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
Recruiting |
NCT06184971 -
Biliary Atresia Research Network Northeast
|
||
Recruiting |
NCT04260503 -
Gut Microbiome in Biliary Atresia
|
||
Not yet recruiting |
NCT06260566 -
Tolerability of Enteral NAC in Infants
|
Phase 1 | |
Completed |
NCT01322386 -
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
|
Phase 1 | |
Recruiting |
NCT05909033 -
Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
|
||
Completed |
NCT03499249 -
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy
|
Phase 2 | |
Recruiting |
NCT05521152 -
Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy
|
Phase 3 | |
Not yet recruiting |
NCT05783518 -
Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06121375 -
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
|
Phase 2/Phase 3 |